- Home
- VINC vs RDHL Comparison
VINC vs RDHL Comparison
Compare VINC & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINC
- RDHL
- Stock Information
- Founded
- VINC 2019
- RDHL 2009
- Country
- VINC United States
- RDHL Israel
- Employees
- VINC N/A
- RDHL N/A
- Industry
- VINC Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- VINC Health Care
- RDHL Health Care
- Exchange
- VINC Nasdaq
- RDHL Nasdaq
- Market Cap
- VINC 6.2M
- RDHL 6.8M
- IPO Year
- VINC N/A
- RDHL N/A
- Fundamental
- Price
- VINC $1.24
- RDHL $4.76
- Analyst Decision
- VINC Buy
- RDHL
- Analyst Count
- VINC 2
- RDHL 0
- Target Price
- VINC $40.00
- RDHL N/A
- AVG Volume (30 Days)
- VINC 1.1M
- RDHL 9.3K
- Earning Date
- VINC 03-28-2025
- RDHL 04-07-2025
- Dividend Yield
- VINC N/A
- RDHL N/A
- EPS Growth
- VINC N/A
- RDHL N/A
- EPS
- VINC N/A
- RDHL N/A
- Revenue
- VINC N/A
- RDHL $3,707,000.00
- Revenue This Year
- VINC N/A
- RDHL $224.90
- Revenue Next Year
- VINC N/A
- RDHL $82.69
- P/E Ratio
- VINC N/A
- RDHL N/A
- Revenue Growth
- VINC N/A
- RDHL N/A
- 52 Week Low
- VINC $1.18
- RDHL $4.76
- 52 Week High
- VINC $187.44
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- VINC 28.95
- RDHL 26.11
- Support Level
- VINC $1.18
- RDHL $5.20
- Resistance Level
- VINC $1.38
- RDHL $5.50
- Average True Range (ATR)
- VINC 0.11
- RDHL 0.23
- MACD
- VINC 0.09
- RDHL -0.07
- Stochastic Oscillator
- VINC 12.50
- RDHL 0.00
About VINC Vincerx Pharma Inc.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.